Key result
Intracoronary CD34+ stem cell transplantation reduced 5-year total mortality compared to no cell therapy (14% vs. 35%; P=0.01) in patients with dilated cardiomyopathy.
Why the study?
Does intracoronary CD34+ stem cell transplantation improve ventricular function, exercise tolerance, and survival in patients with nonischemic dilated cardiomyopathy?
Population
110 patients with nonischemic dilated cardiomyopathy
Comparison
Intracoronary CD34+ stem cell transplantation vs No cell therapy (controls)
Design
RCT, Randomized (55 to stem cell group, 55 to controls)
Follow-up
5 years
Authors
Loading...
Supports intracoronary CD34+ cell therapy in dilated cardiomyopathy; extends prior data to confirmed 5-year survival benefit in RCT.
RCT (n=110)
Does intracoronary CD34+ stem cell transplantation improve ventricular function, exercise tolerance, and survival in patients with nonischemic dilated cardiomyopathy?
Absolute Event Rate: 14% vs 35%
p-value: p=0.01
Intracoronary CD34+ stem cell transplantation in patients with nonischemic dilated cardiomyopathy is associated with long-term improvements in ventricular function, exercise capacity, and survival at 5 years.
Vrtovec et al. (2012) conducted an RCT in Dilated cardiomyopathy (n=110). Intracoronary CD34+ stem cell transplantation vs. No cell therapy was evaluated on Total mortality (p=0.01). Intracoronary CD34+ stem cell transplantation reduced 5-year total mortality compared to no cell therapy (14% vs. 35%; P=0.01) in patients with dilated cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: